AM-Pharma, once a Pfizer takeover target, flunks phase 3 kidney injury trial

Pfizer may have dodged a bullet by walking away from AM-Pharma. The biotech, a onetime takeover target for the Big Pharma, has stopped a phase 3 clinical trial of its kidney injury candidate early after it failed an interim futility analysis.